Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations (original) (raw)

References

  1. Herr HW, Laudone VP, Badalament RA, Oettgen HF, Sogani PC, Freedman BD, Melamed MR, Whitemore WF Jr (1988) Bacillus Calmette–Guérin therapy alters the progression of superficial bladder cancer. J Clin Oncol 6(9):1450–1455
    PubMed CAS Google Scholar
  2. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin. JAMA 271(12):907–913
    Article PubMed CAS Google Scholar
  3. Atzpodien J, Korfer A, Palmer PA, Franks CR, Poliwoda H, Kirchner H (1990) Treatment of metastatic renal cell cancer patients with recombinant subcutaneous human interleukin-2 and interferon-alpha. Ann Oncol 1(5):377–378
    PubMed CAS Google Scholar
  4. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Palen E, Van den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254(5038):1643–1647
    Article PubMed Google Scholar
  5. Esche C, Shurin MR, Lotze MT (1999) The use of dendritic cells for cancer vaccination. Curr Opin Mol Ther 1:72–81
    PubMed CAS Google Scholar
  6. Godelaine D, Carrasco J, Lucas S, Karanikas V, Schuler-Thurner B, Coulie PG, Schuler G, Boon T, Van Pel A (2003) Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. J Immunol 171(9):4893–4897
    Google Scholar
  7. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P (2006) Human T cell responses against melanoma. Annu Rev Immunol 24:175–208
    Article PubMed CAS Google Scholar
  8. Kruit WH, van Ojik HH, Brichard VG, Escudier B, Dorval T, Patel P, van Baren N, Avril MF, Piperno S, Khammari A, Stas M, Ritter G, Lethe B, Godelaine D, Brasseur F, Zhang Y, van der Bruggen P, Boon T, Eggermont AM, Marchand M (2005) Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer 117(4):596–604
    Article PubMed CAS Google Scholar
  9. Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL, Royal RE, Kammula U, Restifo NP, Hughes MS, Schwartzentruber D, Berman DM, Schwarz SL, Ngo LT, Mavroukakis SA, White DE, Steinberg SM (2005) Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 175(9):6169–6176
    PubMed CAS Google Scholar
  10. Anichini A, Vegetti C, Mortarini R (2004) The paradox of T-cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma. Cancer Immunol Immunother 53(10):855–864
    Article PubMed Google Scholar
  11. Wang E, Phan GQ, Marincola FM (2001) T-cell-directed cancer vaccines: the melanoma model. Expert Opin Biol Ther 1(2):277–290
    Google Scholar
  12. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10(9):909–915
    Article PubMed CAS Google Scholar
  13. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlechnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795):1960–1964
    Article PubMed CAS Google Scholar
  14. Wang E, Miller LD, Ohnmacht GA, Mosellin S, Perez-Diez A, Petersen D, Zhao Y, Simon R, Powell JI, Asaki E, Alexander HR, Duray PH, Herlyn M, Restifo NP, Liu ET, Rosenberg SA, Marincola FM (2002) Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 62(13):3581–3586
    PubMed CAS Google Scholar
  15. Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE, Morris JC (2004) Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 113(11):1515–1525
    Google Scholar
  16. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern P (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18(2):89–95
    Article PubMed CAS Google Scholar
  17. Aptsiauri N, Cabrera T, Garcia-Lora A, Lopez-Nevot MA, Ruiz-Cabello F, Garrido F (2007) MHC class I antigens and immune surveillance in transformed cells. Int Rev Cytol 256:139–189
    Google Scholar
  18. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL (1993) Natural history of HLA expression during tumour development. Immunol Today 14:491–499
    Article PubMed CAS Google Scholar
  19. Chang CC, Ferrone S (2007) Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol Immunother 56(2):227–236
    Article PubMed CAS Google Scholar
  20. Garrido F, Algarra I (2001) MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 83:117–158
    Article PubMed CAS Google Scholar
  21. Seliger B, Cabrera T, Garrido F, Ferrone S (2002) HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 12(1):3–13
    Article PubMed CAS Google Scholar
  22. Rolland P, Deen S, Scott I, Durrant L, Splendlove I (2007) Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer. Clin Cancer Res 13(12):3591–3596
    Article PubMed CAS Google Scholar
  23. Kitamura H, Torigoe T, Honma I, Sato E, Asanuma H, Hirohashi Y, Sato N, Tsukamoto T (2006) Effect of human leukocyte antigen class I expression of tumor cells on outcome of intravesical instillation of bacillus calmette–guerin immunotherapy for bladder cancer. Clin Cancer Res 12(15):4641–4644
    Article PubMed CAS Google Scholar
  24. Watson NF, Ramage JM, Madjd Z, Splendlove I, Ellis IO, Scholefield JH, Durrant LG (2006) Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer 118(1):6–10
    Article PubMed CAS Google Scholar
  25. De Baetselier P, Katzav S, Gorelik E, Feldman M, Segal S (1980) Differential expression of H-2 gene products in tumour cells in associated with their metastatogenic properties. Nature 288(5787):179–181
    Article PubMed Google Scholar
  26. Eisenbach L, Hollander N, Greenfield L, Yakor H, Segal S, Feldman M (1984) The differential expression of H-2 K versus H-2D antigens, distinguishing high-metastatic from low-metastatic clones, is correlated with the immunogenic properties of the tumor cells. Int J Cancer 34(4):567–573
    Article PubMed CAS Google Scholar
  27. Saio M, Teicher M, Campbell G, Feiner H, Delgado Y, Frey AB (2004) Immunocytochemical demonstration of down regulation of HLA class-I molecule expression in human metastatic breast carcinoma. Clin Exp Metastasis 21(3):243–249
    Article PubMed CAS Google Scholar
  28. Romero JM, Aptsiauri N, Vazquez F, Cozar JM, Canton J, Cabrera T, Tallada M, Garrido F, Ruiz-Cabello F (2006) Analysis of the expression of HLA class I, proinflammatory cytokines and chemokines in primary tumors from patients with localized and metastatic renal cell carcinoma.Tissue Antigens 68(4):303–310
    Google Scholar
  29. Mendez R, Ruiz-Cabello F, Rodriguez T, Del Campo A, Paschen A, Schedendorf D, Garrido F (2007) Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy. Cancer Immunol Immunother 56(1):88–94
    Article PubMed Google Scholar
  30. Chang CC, Campoli M, Restifo NP, Wang X, Ferrone S (2005) Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy. J Immunol 174(3):1462–1471
    PubMed CAS Google Scholar
  31. Cabrera T, Lara E, Romero JM, Maleno I, Real LM, Ruiz-Cabello F, Valero P, Camacho FM, Garrido F (2007) HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination. Cancer Immunol Immunother 56(5):709–717
    Article PubMed CAS Google Scholar
  32. Carretero R, Romero JM, Ruiz-Cabello F, Maleno I, Rodríguez F, Camacho FM, Real LM, Garrido F, Cabrera T (2008) Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics (in press)
  33. Garcia-Lora A, Algarra I, Gaforio JJ, Ruiz-Cabello F, Garrido F (2001) Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumor variants. Int J Cancer 91(1):109–119
    Article PubMed CAS Google Scholar
  34. Garrido A, Perez M, Delgado C, Garrido ML, Rojano J, Algarra I, Garrido F (1986) Influence of class I H-2 gene expression on local tumor growth. Description of a model obtained from clones derived from a solid BALB/c tumor. Exp Clin Immunogenet 3(2):98–110
    PubMed CAS Google Scholar
  35. Perez M, Algarra I, Ljunggren HG, Mialdea MJ, Gaforio JJ, Klein G, Karre K, Garrido F (1990) A weakly tumorigenic phenotype with high MHC class-I expression is associated with high metastatic potential after surgical removal of the primary murine fibrosarcoma. Int J Cancer 46(2):258–261
    Article PubMed CAS Google Scholar
  36. Algarra I, Gaforio JJ, Garrido A, Mialdea MJ, Perez M, Garrido F (1991) Heterogeneity of MHC-class-I antigens in clones of methylcholanthrene-induced tumors. Implications for local growth and metastasis. Int J Cancer (suppl) 6:73–81
    Google Scholar
  37. Rodriguez T, Mendez R, Del Campo A, Jiménez P, Aptsiauri N, Garrido F, Ruiz-Cabello F (2007) Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines. BMC Cancer 7:34
    Article PubMed CAS Google Scholar
  38. Abril E, Mendez R, Garcia A, Serrano A, Cabrera T, Garrido F, Ruiz-Cabello F (1996) Characterization of a gastric tumor cell line defective in MHC class I inducibility by both alpha- and gamma-interferon. Tissue Antigens 47(5):391–398
    Article PubMed CAS Google Scholar
  39. Khong HT, Wang QJ, Rosenberg SA (2004) Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J Immunother (1997). 27(3):184–190
    Google Scholar
  40. Terabe M, Berzofsky JA (2004) Immunoregulatory T cells in tumor immunity. Curr Opin Immunol 16(2):157–162
    Article PubMed CAS Google Scholar
  41. De Vries TJ, Fourkour A, Wobbes T, Verkroost G, Ruiter DJ, van Muijen GN (1997) Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions.Cancer Res 57(15):3223–3229
    Google Scholar
  42. Bittner M, Metzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, Radmacher M, Simon R, Yakini Z, Ben-dor A, Sampas N, Dougherty E, Wang E, Marincola F, Gooden C, Lueders J, Glatfelter A, Pollock P, Carpten J, Gillanders E, Leja D, Dietrich K, Beaudry C, Berens M, Alberts D, Sondak V (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406(6795):536–540
    Article PubMed CAS Google Scholar
  43. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Brocker EB, Steinman RM, Enk A, Kampgen E, Schuler G (1999) Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190(11):1669–1678
    Article PubMed CAS Google Scholar
  44. Van Baren N, Bonnet MC, Dreno B, Khammari A, Dorval T, Piperno-Neumann S, Lienard D, Speiser D, Marchand M, Brichard VG, Escudier B, Negries S, Dietrich PY, Maraninchi D, Osanto S, Meyer RG, Ritter G, Maingeon P, Tarlaglia J, van der Bruggen P, Coulie PG, Boon T (2005) Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol 23(35):9008–9021
    Article PubMed CAS Google Scholar
  45. Lurquin C, Lethe B, De Plaen E, Corbiere V, Theate I, van Baren N, Coulie PG, Boon T (2005) Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 201(2):249–257
    Article PubMed CAS Google Scholar
  46. Yamshikov GV, Mullins DW, Chang CC, Ogino T, Thompson L, Presley J, Galavotti H, Aquila W, Deacon D, Ross W, Patterson JW, Engelhard VH, Ferrone S, Slingluff CL Jr (2005) Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. J Immunol 174(11):6863–6871
    Google Scholar

Download references